PABIR1

Summary

PABIR1 (PP2A Aalpha (PPP2R1A) and B55A (PPP2R2A) interacting phosphatase regulator 1, HGNC:23490) is a protein-coding gene on chromosome 9q21.11, encoding PPP2R1A-PPP2R2A-interacting phosphatase regulator 1 (Q96E09). Acts as an inhibitor of serine/threonine-protein phosphatase 2A (PP2A) activity. It is a selective cancer dependency (DepMap: 21.5% of cell lines).

Enables protein phosphatase 2A binding activity and protein serine/threonine phosphatase inhibitor activity. Involved in mitotic G2/M transition checkpoint; positive regulation of cell growth; and positive regulation of proteasomal ubiquitin-dependent protein catabolic process. Located in cytoplasm and nuclear body.

Source: NCBI Gene 116224 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 27 total
• Cancer dependency (DepMap): dependent in 21.5% of screened cell lines
• MANE Select transcript: NM_138333

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23490
Approved symbol	PABIR1
Name	PP2A Aalpha (PPP2R1A) and B55A (PPP2R2A) interacting phosphatase regulator 1
Location	9q21.11
Locus type	gene with protein product
Status	Approved
Aliases	MGC17347
Ensembl gene	ENSG00000187866
Ensembl biotype	protein_coding
OMIM	617249
Entrez	116224

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000394264

RefSeq mRNA: 1 — MANE Select: NM_138333 NM_138333

CCDS: CCDS6623

Canonical transcript exons

ENST00000394264 — 1 exons

Exon	Start	End
ENSE00002240002	68780065	68785566

Expression profiles

Bgee: expression breadth ubiquitous, 242 present calls, max score 94.50.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.1511 / max 126.0962, expressed in 1810 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
96806	18.8248	1810
96808	0.2321	93
96807	0.0942	48

Top tissues by expression

251 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	94.50	gold quality
oocyte	CL:0000023	91.63	gold quality
epithelial cell of pancreas	CL:0000083	91.63	gold quality
tibialis anterior	UBERON:0001385	90.07	silver quality
biceps brachii	UBERON:0001507	88.74	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	88.44	gold quality
deltoid	UBERON:0001476	87.44	silver quality
heart right ventricle	UBERON:0002080	86.73	gold quality
popliteal artery	UBERON:0002250	83.41	gold quality
tibial artery	UBERON:0007610	83.38	gold quality
pigmented layer of retina	UBERON:0001782	83.30	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.06	gold quality
quadriceps femoris	UBERON:0001377	82.79	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.73	gold quality
vastus lateralis	UBERON:0001379	82.71	gold quality
right coronary artery	UBERON:0001625	82.67	gold quality
descending thoracic aorta	UBERON:0002345	82.62	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	82.43	gold quality
left coronary artery	UBERON:0001626	82.38	gold quality
aorta	UBERON:0000947	82.26	gold quality
skeletal muscle tissue	UBERON:0001134	81.77	gold quality
esophagus squamous epithelium	UBERON:0006920	81.51	gold quality
ileal mucosa	UBERON:0000331	81.32	gold quality
myocardium	UBERON:0002349	81.26	silver quality
endothelial cell	CL:0000115	81.24	silver quality
coronary artery	UBERON:0001621	81.05	gold quality
thoracic aorta	UBERON:0001515	81.04	gold quality
islet of Langerhans	UBERON:0000006	80.90	gold quality
ascending aorta	UBERON:0001496	80.81	gold quality
muscle tissue	UBERON:0002385	80.80	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

194 targeting PABIR1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-548N	99.98	71.94	4170
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-6778-3P	99.96	67.29	2693

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 21.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 6)

• identify FAM122A as a new endogenous PP2A inhibitor (PMID:27588481)
• FAM122A promotes acute myeloid leukemia cell growth through inhibiting PP2A activity and sustaining MYC expression. (PMID:32354864)
• FAM122A Inhibits Erythroid Differentiation through GATA1. (PMID:32763160)
• FAM122A maintains DNA stability possibly through the regulation of topoisomerase IIalpha expression. (PMID:32866497)
• FAM122A is required for hematopoietic stem cell function. (PMID:33262527)
• FAM122A ensures cell cycle interphase progression and checkpoint control by inhibiting B55alpha/PP2A through helical motifs. (PMID:38982062)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	pabir2	ENSDARG00000036500
mus_musculus	Pabir1	ENSMUSG00000074922
rattus_norvegicus	Pabir1	ENSRNOG00000051051
drosophila_melanogaster	CG4497	FBGN0031895
caenorhabditis_elegans		WBGENE00018518

Paralogs (2): PABIR3 (ENSG00000156500), PABIR2 (ENSG00000156504)

Protein

Protein identifiers

PPP2R1A-PPP2R2A-interacting phosphatase regulator 1 — Q96E09 (reviewed: Q96E09)

Alternative names: PABIR family member 1

All UniProt accessions (1): Q96E09

UniProt curated annotations — full annotation on UniProt →

Function. Acts as an inhibitor of serine/threonine-protein phosphatase 2A (PP2A) activity. Inhibits PP2A activity by blocking the substrate binding site on PPP2R2A and the active site of PPP2CA. Potentiates ubiquitin-mediated proteasomal degradation of serine/threonine-protein phosphatase 2A catalytic subunit alpha (PPP2CA). Inhibits PP2A-mediated dephosphorylation of WEE1, promoting ubiquitin-mediated proteolysis of WEE1, thereby releasing G2/M checkpoint.

Subunit / interactions. Interacts with PPP2CA and PPP2R1A. Interacts (via its N-terminus) with PPP2R2A; the interaction is direct and this interaction inhibits PP2A activity. The CHEK1-mediated Ser-37 phosphorylated form interacts with 14-3-3 proteins.

Subcellular location. Nucleus. Cytoplasm.

Post-translational modifications. CHEK1-mediated phosphorylation at Ser-37 negatively regulates its ability to inhibit serine/threonine-protein phosphatase 2A (PP2A) activity. Phosphorylation leads to its release from the PP2A complex and its sequestration by 14-3-3 proteins in the cytoplasm resulting in its inability to translocate to the nucleus, where it otherwise inhibits PP2A.

Similarity. Belongs to the FAM122 family.

RefSeq proteins (1): NP_612206* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026716	PBIR1/2/3	Family

UniProt features (33 total): modified residue 15, mutagenesis site 7, compositionally biased region 4, region of interest 3, helix 2, chain 1, cross-link 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
8TWE	ELECTRON MICROSCOPY	2.55
8TWI	ELECTRON MICROSCOPY	2.69
8SO0	ELECTRON MICROSCOPY	2.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96E09-F1	60.54	0.08

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (16): 45, 47, 48, 62, 76, 143, 147, 149, 187, 189, 267, 270, 276, 89, 35, 37

Mutagenesis-validated functional residues (7):

Position	Phenotype
37	loss of phosphorylation and interaction with 14-3-3 proteins. enhanced interaction with ppp2r2a.
84–85	impairs interaction with ppp2r2a and reduces the inhibition of pp2a activity by pabir1/fam122a.
88–89	impairs interaction with ppp2r2a and reduces the inhibition of pp2a activity by pabir1/fam122a.
91	impairs interaction with ppp2r2a and reduces the inhibition of pp2a activity by pabir1/fam122a.
92	impairs interaction with ppp2r2a and reduces the inhibition of pp2a activity by pabir1/fam122a.
105	reduces the inhibition of pp2a activity by pabir1/fam122a.
107	reduces the inhibition of pp2a activity by pabir1/fam122a.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 225 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, AGGAAGC_MIR5163P, GOBP_REGULATION_OF_PROTEASOMAL_UBIQUITIN_DEPENDENT_PROTEIN_CATABOLIC_PROCESS, TGCGCANK_UNKNOWN, GOZGIT_ESR1_TARGETS_DN, GOBP_CELL_CYCLE_PHASE_TRANSITION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_GROWTH, GOBP_POSITIVE_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GGAMTNNNNNTCCY_UNKNOWN, GOBP_MITOTIC_G2_M_TRANSITION_CHECKPOINT, GOBP_REGULATION_OF_CELL_CYCLE_G2_M_PHASE_TRANSITION

GO Biological Process (3): positive regulation of cell growth (GO:0030307), positive regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032436), mitotic G2/M transition checkpoint (GO:0044818)

GO Molecular Function (4): protein phosphatase inhibitor activity (GO:0004864), protein serine/threonine phosphatase inhibitor activity (GO:0004865), protein phosphatase 2A binding (GO:0051721), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), nuclear body (GO:0016604)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
regulation of cell growth	1
cell growth	1
positive regulation of growth	1
positive regulation of cellular process	1
regulation of proteasomal ubiquitin-dependent protein catabolic process	1
proteasome-mediated ubiquitin-dependent protein catabolic process	1
positive regulation of proteasomal protein catabolic process	1
positive regulation of ubiquitin-dependent protein catabolic process	1
mitotic cell cycle checkpoint signaling	1
negative regulation of G2/M transition of mitotic cell cycle	1
phosphoprotein phosphatase activity	1
phosphatase inhibitor activity	1
protein phosphatase regulator activity	1
protein serine/threonine phosphatase activity	1
protein phosphatase inhibitor activity	1
protein phosphatase binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
nucleoplasm	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

250 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PABIR1	OGFOD1	Q8N543	607
PABIR1	PIP5K1B	P78518	478
PABIR1	INTS15	Q96N11	446
PABIR1	ZFYVE19	Q96K21	446
PABIR1	PRKAG2	Q9UGJ0	402
PABIR1	ENSA	O43768	398
PABIR1	CIP2A	Q8TCG1	380
PABIR1	UBE2Q2	Q8WVN8	325
PABIR1	NAIF1	Q69YI7	325
PABIR1	PHTF2	Q8N3S3	323
PABIR1	NKAPL	Q5M9Q1	322
PABIR1	DCUN1D4	Q92564	318
PABIR1	ADGRF2P	Q8IZF7	317
PABIR1	ARPP19	P56211	310
PABIR1	MIGA1	Q8NAN2	310

IntAct

57 interactions, top by confidence:

A	B	Type	Score
PPP2R1A	PPP2R2A	psi-mi:“MI:0915”(physical association)	0.970
PPP2R2A	PPP2R1A	psi-mi:“MI:0915”(physical association)	0.970
PABIR1	PPP2R1A	psi-mi:“MI:0914”(association)	0.880
PPP2R1A	STRN	psi-mi:“MI:0914”(association)	0.880
PPP2R2A	PABIR1	psi-mi:“MI:0407”(direct interaction)	0.820
PABIR1	PPP2R2A	psi-mi:“MI:0407”(direct interaction)	0.820
PPP2R2C	PPP2R1A	psi-mi:“MI:0914”(association)	0.730
POLR3GL	POLR3A	psi-mi:“MI:0914”(association)	0.730
PPP2R2D	YEATS4	psi-mi:“MI:0914”(association)	0.730
YWHAG	BLTP3B	psi-mi:“MI:2364”(proximity)	0.640
PPP2R2A	ARPP19	psi-mi:“MI:0407”(direct interaction)	0.630
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
YWHAH	BLTP3B	psi-mi:“MI:2364”(proximity)	0.570
PPP2R2A	RBL1	psi-mi:“MI:0915”(physical association)	0.540
PPP2R1A	ENSA	psi-mi:“MI:0914”(association)	0.530
PABIR1	TERF2IP	psi-mi:“MI:0915”(physical association)	0.510
	PABIR1	psi-mi:“MI:0203”(dephosphorylation reaction)	0.440
PKM	PABIR1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
Ppp2r1a	CCHCR1	psi-mi:“MI:0914”(association)	0.350
KIF11	ILVBL	psi-mi:“MI:0914”(association)	0.350
PPP2R1A	INTS2	psi-mi:“MI:0914”(association)	0.350
Ppp2r2a	PPP2R1A	psi-mi:“MI:0914”(association)	0.350

BioGRID (65): FAM122A (Affinity Capture-MS), KLHL15 (Affinity Capture-MS), PPP2R1A (Affinity Capture-MS), PPP3CA (Affinity Capture-MS), FAM122B (Affinity Capture-MS), PPP2R2D (Affinity Capture-MS), PPP2R2A (Affinity Capture-MS), PPP3R1 (Affinity Capture-MS), RCAN1 (Affinity Capture-MS), FAM122A (Affinity Capture-MS), FAM122A (Affinity Capture-MS), FAM122A (Affinity Capture-MS), FAM122A (Affinity Capture-MS), FAM122A (Affinity Capture-MS), FAM122A (Affinity Capture-MS)

ESM2 similar proteins: A2AQ25, A4IGU9, A7E300, A8E4V2, B5DF41, B5DGK1, F1N4M2, O15079, O55003, O60238, O60516, Q0IHF8, Q0P5A7, Q12983, Q13541, Q14DQ1, Q1LWL8, Q3B7T9, Q3T013, Q3UN70, Q3ZCB6, Q5PR01, Q5XG16, Q5XKK7, Q5ZLN7, Q60876, Q62622, Q62739, Q63744, Q68EF0, Q68FF7, Q6AYT4, Q6PBI2, Q6PFP3, Q6ZNC4, Q7Z309, Q80U23, Q80VV3, Q8AVU0, Q8LD26

Diamond homologs: Q5ZLN7, Q6AYT4, Q6NZE7, Q6P4D5, Q7Z309, Q96E09, Q9DB52

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
PABIR1	“down-regulates activity”	PPP2R2A	binding
CHEK1	“down-regulates activity”	PABIR1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 47 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	7	152.3×	9e-13
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	134.3×	2e-12
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	134.3×	2e-12
Activation of BH3-only proteins	7	99.3×	2e-11
RHO GTPases activate PKNs	7	63.4×	4e-10
Intrinsic Pathway for Apoptosis	7	58.6×	7e-10
FOXO-mediated transcription	6	57.6×	2e-08
RAF activation	5	48.0×	6e-07

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	5	44.7×	1e-05
mitotic cell cycle	7	22.8×	6e-06
intracellular protein localization	7	17.9×	1e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

27 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	26
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

184 predictions. Top by Δscore:

Variant	Effect	Δscore
9:68781019:GTC:G	donor_gain	0.9600
9:68781020:TCT:T	donor_gain	0.9600
9:68781021:C:G	donor_gain	0.9600
9:68781025:G:GG	donor_gain	0.9000
9:68780947:C:A	donor_gain	0.8800
9:68781021:C:CG	donor_gain	0.8700
9:68781024:A:AG	donor_gain	0.8700
9:68780652:GTTTT:G	donor_gain	0.8500
9:68780945:G:GG	donor_gain	0.8500
9:68781029:T:G	donor_gain	0.8500
9:68780290:C:CA	acceptor_gain	0.8300
9:68780623:G:T	donor_gain	0.8300
9:68780944:A:AG	donor_gain	0.8200
9:68780623:G:GT	donor_gain	0.8000
9:68780657:G:GG	donor_gain	0.8000
9:68780942:A:T	donor_gain	0.7800
9:68780501:A:G	donor_gain	0.7700
9:68781028:A:AG	donor_gain	0.7400
9:68780520:A:T	donor_gain	0.7200
9:68780932:C:G	donor_gain	0.7200
9:68781505:T:A	donor_gain	0.7100
9:68780653:TTTT:T	donor_gain	0.7000
9:68780654:TTTG:T	donor_loss	0.6400
9:68780655:TTG:T	donor_loss	0.6400
9:68780656:TG:T	donor_loss	0.6400
9:68780657:G:GC	donor_loss	0.6400
9:68780658:TAA:T	donor_loss	0.6400
9:68780659:A:AC	donor_loss	0.6400
9:68780660:AGTAG:A	donor_loss	0.6400
9:68780661:G:C	donor_loss	0.6400

AlphaMissense

1882 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:68780633:T:C	F157L	0.999
9:68780635:T:A	F157L	0.999
9:68780635:T:G	F157L	0.999
9:68780776:A:C	R204S	0.999
9:68780776:A:T	R204S	0.999
9:68780265:G:T	R34M	0.998
9:68780427:T:C	I88T	0.998
9:68780427:T:G	I88S	0.998
9:68780478:G:C	R105P	0.998
9:68780273:A:C	S37R	0.997
9:68780275:C:A	S37R	0.997
9:68780275:C:G	S37R	0.997
9:68780513:T:A	W117R	0.997
9:68780513:T:C	W117R	0.997
9:68780607:C:A	P148H	0.997
9:68780773:A:C	K203N	0.997
9:68780773:A:T	K203N	0.997
9:68780775:G:C	R204T	0.997
9:68780286:T:C	I41T	0.996
9:68780431:A:C	K89N	0.996
9:68780431:A:T	K89N	0.996
9:68780460:G:C	R99P	0.996
9:68780492:G:C	A110P	0.996
9:68780606:C:T	P148S	0.996
9:68780626:G:C	K154N	0.996
9:68780626:G:T	K154N	0.996
9:68780753:A:C	S197R	0.996
9:68780755:T:A	S197R	0.996
9:68780755:T:G	S197R	0.996
9:68780771:A:G	K203E	0.995

dbSNP variants (sampled 300 via entrez): RS1000762651 (9:68778099 T>C), RS1000779266 (9:68781319 ATAAC>A), RS1001186345 (9:68782324 A>G), RS1001818969 (9:68781922 C>T), RS1001883948 (9:68783237 T>C), RS1001916520 (9:68782833 ATCT>A), RS1001995024 (9:68785002 G>T), RS1002799471 (9:68781162 G>T), RS1002877105 (9:68779597 G>C), RS1003177627 (9:68781610 A>G,T), RS1003556675 (9:68784749 A>G), RS1004130584 (9:68778441 AC>A), RS1004440950 (9:68783022 T>A), RS1004807206 (9:68784185 A>G), RS1004856248 (9:68779111 G>A)

Disease associations

OMIM: gene MIM:617249 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST000649_28	Chronic kidney disease	8.000000e-14
GCST007876_57	Estimated glomerular filtration rate	7.000000e-31

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
GSK-J4	decreases expression	1
FR900359	affects phosphorylation	1
triphenyl phosphate	affects expression	1
kojic acid	increases expression	1
coumarin	increases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
cylindrospermopsin	increases expression	1
Sunitinib	increases expression	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Atrazine	decreases expression	1
Caffeine	affects phosphorylation	1
Doxorubicin	decreases expression	1
Quercetin	affects phosphorylation	1
Urethane	decreases expression	1
Vanadates	decreases expression	1
Aflatoxin B1	decreases methylation	1
Antirheumatic Agents	increases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1
Genistein	increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SM82	HAP1 FAM122A (-) 1	Cancer cell line	Male
CVCL_XN63	HAP1 FAM122A (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.